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Abstract
Background: Few studies have focused on the cognitive morbidity of neurocysticercosis (NCC), one of the most common
parasitic infections of the central nervous system. We longitudinally assessed the cognitive status and quality of life (QoL) of
patients with incident symptomatic NCC cases and matched controls.
Methodology/Principal Findings: The setting of the study was the Sabogal Hospital and Cysticercosis Unit, Department of
Transmissible Diseases, National Institute of Neurological Sciences, Lima, Peru. The design was a longitudinal study of new
onset NCC cases and controls. Participants included a total of 14 patients with recently diagnosed NCC along with 14
healthy neighborhood controls and 7 recently diagnosed epilepsy controls. A standardized neuropsychological battery was
performed at baseline and at 6 months on NCC cases and controls. A brain MRI was performed in patients with NCC at
baseline and 6 months. Neuropsychological results were compared between NCC cases and controls at both time points. At
baseline, patients with NCC had lower scores on attention tasks (p,0.04) compared with epilepsy controls but no
significant differences compared to healthy controls. Six months after receiving anti-parasitic treatment, the NCC group
significantly improved on tasks involving psychomotor speed (p,0.02). QoL at baseline suggested impaired mental
function and social function in both the NCC and epilepsy group compared with healthy controls. QoL gains in social
function (p=0.006) were noted at 6 months in patients with NCC.
Conclusions/Significance: Newly diagnosed patients with NCC in this sample had mild cognitive deficits and more marked
decreases in quality of life at baseline compared with controls. Improvements were found in both cognitive status and
quality of life in patients with NCC after treatment.
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Introduction
Neurocysticercosis (NCC) is caused by an infection of the human
central nervous system (CNS) by the larval stage of the pork
tapeworm Taenia solium. NCC is one of the most common parasitic
infections of the human CNS and has become an increasingly
important emerging infection in the United States [1]. It is the most
common cause of symptomatic epilepsy worldwide [2,3].
NCC is a dynamic, pleomorphic disease due to the variety of
locations, numbers, and stages of lesions within the individual host
[4]. The disease may mimic many neurologic syndromes, and a
uniform presentation has not been described. Seizures are the
most commonly reported symptom at presentation, occurring in
up to 50–80% of patients [5,6]. Headaches and focal neurologic
deficits are also common.
Patients with NCC often display cognitive impairment. Mild to
moderate cognitive dysfunction has been reported in up to 88% of
NCC patients [7]. Dementia, defined through bedside testing,
has been found in 6 to 15% of NCC patients in large clinical
series [5,8]. Levav, et al was the first group to use a standardized
neuropsychological battery in assessing the cognitive status of
patients with NCC [9]. They found significant deficits in motor
control and impulsivity in NCC cases compared to controls. More
recently, Ciampi De Andrade, et al used a comprehensive
neuropsychological battery to evaluate a group of patients with
NCC and matched healthy and epilepsy controls [10]. The group
found impairment in multiple cognitive domains in patients with
NCC prior to treatment as compared to both groups of controls.
The use of antiepileptic drugs and seizures did not account for the
cognitive abnormalities.
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NCC have been cross-sectional in nature. Because NCC is a
heterogeneous disorder with great differences in disease duration,
clinical features, and disability, it is important to control for as
many of these factors as possible. Several unanswered questions
remain about the temporal nature of cognitive dysfunction in the
disease. For example, how do cognitive changes evolve over time?
Are there risk factors that influence the course? Finally, what is the
impact of NCC on the quality of life of patients with this infection?
We used a comprehensive standardized battery to assess the
cognitive status of patients with newly diagnosed NCC at baseline
and at six months. A group of demographically matched healthy
neighborhood controls and epilepsy controls were recruited for
comparison. Similar to NCC cases, the epilepsy controls had new
onset seizures to adjust for the effects of antiepileptics on cognitive
performance.
Methods
Ethical Considerations
This study was approved by the Institutional Review Board
(IRB) at the of the Universidad Peruana Cayetano Heredia, the
Instituto Nacional de Ciencias Neurologicas, and the Hospital
Alberto Sabogal all in Lima, Peru, as well as the IRBs of
Georgetown University and the VA Medical Center, both in
Washington, DC. All subjects enrolled in the study provided
written informed consent.
Study Participants
A total of 14 patients with NCC were recruited at the Sabogal
Hospital and Cysticercosis Unit, Department of Transmissible
Diseases, National Institute of Neurological Sciences in Lima,
Peru. To make the baseline time point consistent across cases,
patients with NCC were recruited within six months of a new-
onset seizure associated with parenchymal NCC. These incident
symptomatic cases had a positive serologic enzyme-linked
immunotransfer blot (EITB) assay and met standard diagnostic
criteria for NCC [11]. Seizures must have been controlled with
standard antiepileptic drugs (AED) for inclusion. Exclusion criteria
for cases included central nervous system disease not related to
NCC, active alcohol or drug abuse, primary psychiatric disease
prior to developing NCC, disorders of vision that would preclude
cognitive testing and pregnancy.
For comparison, 14 healthy neighborhood controls were
recruited along with the NCC cases. Healthy controls were
recruited from the neighborhood of the patients with NCC and
were matched to cases on age (+/210 years) and education (+/25
years). Controls were EITB negative, had no chronic health
conditions and had similar exclusion criteria as cases.
Epilepsy controls were also recruited at the Sabogal Hospital
after new onset seizures (N=7). Epilepsy was defined according to
revised criteria from the International League against Epilepsy
[12]. All seven epilepsy controls had a brain CT prior to
enrollment which was normal. Seizures were both generalized and
focal and their epilepsy was classified as unknown etiology.
Seizures were controlled in all subjects with standard AEDs. All
epilepsy controls were EITB negative, and met exclusion criteria
as per NCC cases.
Procedures
All patients participating in the study had a screening history
and physical at baseline. Patients with NCC were treated with a
standard 10-day course of albendazole [13] (15 mg/kg/day
divided bid) and started on an AED regime that was consistent
throughout the 6 month follow-up period. Similarly, patients with
new onset seizures were started on a standard AED regime during
the study period. Neuropsychological testing was performed at a
mean interval of 8 weeks from starting AED medications for new
onset epilepsy cases and a mean interval of 11 weeks after
completing antihelminthic medication and initiating AEDs for
new onset NCC cases.
A brain MRI was performed at baseline and month 6 for all
NCC patients at a private radiological center on a 1.5-Tesla unit,
as in previous trials [13,14]. The protocol included T-1 weighted
axial with and without intravenous gadolinium (0.1 mmol/kg),
and T2-weighted and FLAIR axial studies. A radiologist
experienced with NCC cases read each imaging study to
determine the number, stage and location of CNS parenchymal
cysticerci. Cure rate was determined by the number of patients
who had resolution of cysts by brain MRI at 6 month follow-up.
Neuropsychological Testing Battery
The neuropsychology testing battery for the current study,
administered at baseline and 6 month follow-up to all patients, was
chosen to tap into the various domains of cognitive functioning
thought to be affected by NCC. It is sensitive to lapses in attention,
decreased visual and motor processing, and problems with
working memory. It was developed in consultation with Dr.
Mirsky based on his experience of testing NCC patients in
Ecuador [9]. In addition, a standard quality of life (QoL)
instrument, the SF-36, was included in the battery. The tests in
the battery are listed and referenced under their cognitive domain
in Table 1. All tests were administered by a single native Spanish
speaking psychology technician using standard Spanish transla-
tions of each test. The instructions for tests were given to patients
in Spanish using a standard script.
Statistical Analysis
Group means for individual neuropsychological tests at each
visit (baseline, and 6 months) were calculated for NCC cases and
controls. SF-36 transformed scale scores were calculated from the
raw scale scores. A p-value#0.05 was considered significant.
Differences between groups were assessed by the x2 test for
categorical variables and the t-test for continuous variables.
Because there are no national normative data for Peru, results
for the NCC cases were assessed in the context of healthy controls,
and epilepsy controls.
Author Summary
Neurocysticercosis (NCC) is one of the most common
parasitic infections of the central nervous system. Cogni-
tive changes have been frequently reported with this
disease but have not been well studied. Our study team
recruited a group of new onset NCC cases and a matched
set of healthy neighborhood controls and new onset
epilepsy controls in Lima, Peru for this study. A neuropsy-
chological battery was administered at baseline and at 6
months to all groups. Brain MRI studies were also obtained
on NCC cases at baseline and at 6 months. Newly
diagnosed patients with NCC had mild cognitive deficits
and more marked decreases in quality of life at baseline
compared with controls. Improvements were found in
both cognitive status and quality of life in patients with
NCC after treatment. This study is the first to assess
cognitive status and quality of life longitudinally in
patients with NCC and provides new data on an important
clinical morbidity outcome.
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administered, a composite score was computed for the assessed
cognitive domains. The tests comprising the composite scores for
the major cognitive domains of attention, processing speed,
learning and memory are defined in Table 1. Additional tests
covering the following neuropsychological areas are also included
in the battery: a) vigilance/sustained attention; b) general cognitive
function; c) affect; and d) quality of life. These tests were not part
of the composite scores.
The composite score is made up of the individual tests within
the specified domain and is highly correlated to the individual test
scores. Using composite scores focuses the analysis on specific
cognitive domains and reduces the likelihood of making Type 1
errors by minimizing the number of variables in the analysis.
Composite scores also attenuate ceiling and floor effects of
individual test scores and are helpful in finding longitudinal
changes when there is heterogeneity in cognitive function [15,16].
In each case, raw scores were converted into z-scores based on US
population-based normative data for each standardized test. The
z-scores were averaged within each domain yielding a standard-
ized measure of a participant’s (both cases and controls) average
performance on key measures within each cognitive domain. For
example, the memory composite score was calculated by adding
the individual z-scores of the Wechsler Memory Scale -III Logical
Memory II and the Rey Auditory Verbal Learning Test delayed
recall and dividing by 2, the total number of scores in the index.
We used both one-way and multiple ANOVA to examine how
NCC cases performed on various measures of neuropsychological
function and QoL as compared with controls at each testing time
point. We also compared changes in neuropsychological testing
scores longitudinally within the same group using t-tests. For
multiple regression, demographic and variables were entered as
covariates in the standard linear models. Adjustments were not
made for multiple comparisons. Within the four composite
cognitive domains, we considered a z-score below 1.5 standard
deviations to be impaired. We compared the proportion of
subjects that were impaired between groups at the baseline
assessment. SPSS version 14 (Chicago, IL) was used for the
statistical analysis.
Results
There were no statistically significant differences in the major
demographic variables (Table 2) among the NCC cases,
neighborhood controls and epilepsy cases in this study. There
were no clinical seizures during the study follow-up period in
either the NCC cases or epilepsy controls. Patients with NCC and
epilepsy remained on the initial antiepileptic therapy they were
prescribed during the 6-month study follow-up period. There were
no cases of hydrocephalus or increased intracranial pressure in the
NCC group per neuroimaging at any time point in the study.
Comparisons were made among the groups (NCC, neighbor-
hood healthy controls, and epilepsy controls) at baseline using
multiple ANOVA (Table 3) with scores adjusted for age and
education. At baseline, patients with NCC had lower Attention
Composite Scores than the epilepsy controls (p,0.04). For other
composite cognitive domains, patients with NCC generally scored
lower than controls. However, there were no significant differences
in baseline composite scores for learning, memory, processing
speed or other neuropsychological tests when comparing NCC
cases with epilepsy controls or NCC cases with neighborhood
controls (all p$0.13).
The proportion of cognitively impaired patients with NCC at
baseline within the composite domains of attention, processing
speed, learning and memory was 57%, 57%, 50% and 36%
respectively. Similarly, neighborhood controls had 43%, 43%,
29% and 29% of subjects impaired in the same respective
cognitive domains. Epilepsy controls had 14% impairment in
each of the composite domains. Overall, there was a greater trend
for patients with NCC to be impaired in all four cognitive
composites when compared with neighborhood controls and
epilepsy controls.
QoL summary scores at baseline revealed a significant
decrement in social function (p=0.002) and borderline decreases
in physical function (p=0.067) and mental function (p=0.072) in
the NCC group compared with neighborhood controls (Table 4).
Epilepsy controls had a significant QoL decrease in mental health
function (p=0.028) and borderline low social function (p=0.065)
compared with neighborhood controls. The number of seizures at
onset were not significantly correlated with any baseline QoL
summary score.
QoL scores at the six month follow-up visit showed an overall
trend for improvement across physical health, mental health and
social function domains in both NCC and epilepsy groups
(Table 4). There were no significant or borderline differences
cross-sectionally between any group with all p values.0.1.
All groups were examined for cognitive changes over time (i.e.,
between baseline and 6-month follow-up testing). Within the
cognitive battery of tests, NCC cases had significant improvement
in psychomotor speed and working memory as assessed by the
WAIS-III Digit Symbol Coding Subtest (p=0.012) and by the
Trail Making Test Part B (p=0.016) between the baseline and 6-
month follow-up sessions but there were no significant changes in
any composite score (Table 5).
Table 1. Neuropsychological testing battery.
Neuropsychological Domain Test
Vigilance/Sustained Attention Kay Continuous Performance Test [27]
Processing Speed Stroop Color & Word Test [28]
Talland Letter Cancellation Test [29]
#Trail Making Test (Parts A and B) [30]
#WAIS-III [31]: Digit Symbol-Coding Test
Simple/Complex Attention *WAIS-III [31]: Digit Span Test
*WAIS-III [31]: Arithmetic Test
WMS-III [32]: Mental Control
Learning/Encoding "WMS-III [32]: Logical Memory I
"RAVLT [33] Trials 1–5
Memory/Recall 1WMS-III [32] Logical Memory II
1RAVLT [33] Delayed Recall
Problem Solving/Reasoning Wisconsin Card Sorting Test [34]
Ravens Standard Progressive Matrices [35]
General Cognitive Function Mini-Mental Status Examination [36]
Affect Beck Depression Inventory [37]
Beck Anxiety Inventory [38]
Quality of Life SF-36 [39]
*Attention composite tests;
#Processing speed composite tests;
"Learning composite tests;
1Memory composite tests (see Table 3).
Abbreviations: WAIS: Wechsler Adult Intelligence Scale, WMS: Wechsler Memory
Scale, RAVT: Raven’s Progressive Matrices and Vocabulary Scales, SF-36: Short
Form-36.
doi:10.1371/journal.pntd.0001493.t001
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the SF-36 domain assessing social function (p=0.0062) over the 6-
month follow-up period (Table 4). Despite improved scores for
NCC and epilepsy groups between baseline and follow-up visits,
there were no other significant or borderline longitudinal changes
in the remaining QoL domains for any of the 3 patient groups (p
values.0.4).
Among the demographic and clinical variables collected in the
study, there were no significant longitudinal predictors of cognitive
dysfunction or QoL in any group. Variables utilized in bivariate
and multivariate statistical models included age, sex, education,
occupation, number of CNS cysts, type of cysts, and cure rate of
cysts.
Discussion
This study demonstrated that patients with parenchymal NCC
had relatively mild cognitive dysfunction shortly after presenta-
tion of seizures compared with two sets of control groups.
Moreover, quality of life was significantly impaired in the NCC
and epilepsy groups compared with healthy controls. Many
reports of altered cognition in NCC have been related to
Table 2. Demographic and clinical summary of neurocysticercosis cases and controls.
Demographic & Clinical Variables
NCC Cases
(N=14)
Neighborhood Controls
(N=14)
Epilepsy Controls
(N=7)
Age (yrs at baseline), mean (SD) 28 (10) 28 (10) 30 (6)
Male sex (no.) 10 6 4
Education: n (%)
0–8 yrs 5 (36) 1 (7) 1 (0)
9–12 yrs 3 (21) 6 (43) 3 (43)
.12 yrs 6 (43) 7 (50) 4 (57)
Occupational status:
Unemployed: n (%) 0 (0) 0 (0) 0 (0)
Student: n (%) 5 (36) 2 (14) 0 (0)
Employed nonprofessional: n (%) 8 (57) 9 (64) 3 (43)
Employed professional: n (%) 1 (7) 3 (21) 4 (57)
Number of cysts (baseline)
Total: median (IR) 2 (5.8) - -
Cysts w/o degeneration: median (IR) 1.5 (4.8) - -
Cysts with degeneration: median (IR) 1.0 (1.0) - -
Calcified cysts: median (IR) 0 (0) - -
Antiepileptic medication: n (%)
Phenytoin 9 (64) - 3 (43)
Carbamazepine 4 (29) - 3 (43)
Clonazepam 0 (0) - 1 (14)
Valproate & Carbamazepine 1 (7) - 0 (0)
Baseline number of seizures: mean (SD) 2.7 (1.9) - 2.1 (0.4)
Seizure type:
Generalized: n (%) 6 (43) - 6 (86)
Partial: n (%) 2 (14) - 1 (14)
Both Generalized & Partial: n (%) 6 (43) - 0 (0)
Abbreviations: SD: standard deviation, IR: interquartile range.
doi:10.1371/journal.pntd.0001493.t002
Table 3. Composite age and education-adjusted test scores for major cognitive domains at baseline and 6-month follow-up.
Attention Processing Speed Learning Memory
Group Baseline Follow-up Baseline Follow-up Baseline Follow-up Baseline Follow-up
NCC 34.0 (9.0)** 35.5 (9.8) 31.5 (10.2) 33.0 (11.3) 37.7 (12.2) 41.3 (12.0) 39.7 (9.4) 40.5 (11.3)
Epilepsy Controls 44.0 (8.4) 43.8(6.5) 38.1 (5.2) 41.1 (6.3) 44.3 (7.0) 49.8 (6.4) 43.2 (6.3) 51.0 (5.7)
Neighborhood Controls 36.7 (7.2) 37.4 (3.9) 34.5 (11.4) 36.0 (9.0) 41.1 (8.9) 41.3 (7.4) 40.7 (7.6) 44.5 (5.8)
**Significant difference between NCC and Epilepsy groups cross-sectionally (p#0.05). Standard deviation follows test scores in brackets.
doi:10.1371/journal.pntd.0001493.t003
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case in this series.
After six months of follow-up, cognitive tasks involving
attention/psychomotor speed and working memory improved in
patients with NCC as did QoL. There were no significant
demographic or clinical predictors of cognitive dysfunction or
QoL in NCC cases or controls. This is the first study to
longitudinally assess cognitive function and QoL in patients with
NCC.
There are few publications that have specifically addressed
cognitive changes in NCC. Most of the information on this topic
comes from case series and anecdotal reports of NCC patients who
experience psychiatric disturbances or mental status changes. How
the cysticercotic CNS lesions exert their effects on cognition is
unclear, but at least some of the mental status changes described in
clinical reports could be explained by partial seizures, mass effect
of cysts and increased intracranial pressure. The inflammatory
immune response is critical in NCC pathogenesis but is poorly
understood. CNS inflammation has been correlated with the
cognitive dysfunction in a number of neurological conditions
including multiple sclerosis and Alzheimer’s dementia [17,18].
Finally, the effects of AEDs on cognition in patients with epilepsy
has been well studied [19]. Controlling for these effects with an
epilepsy control group is prudent.
Longitudinal improvement trends in QoL were seen in patients
with both NCC and epilepsy in this study. The mechanisms for
decrements in QoL may be different than those producing
cognitive dysfunction. Reduction in seizures which was seen in
both the epilepsy and NCC groups over the follow-up period may
be playing a role in improved QoL outcomes. We did not see a
significant correlation between the number of seizure and QoL at
baseline, however.
The earliest reports of mental status changes with NCC come
from case series in the early 20
th century, where both clinical and
pathologic aspects are described [1,2]. Other early reports
emphasize the importance of altered mental status as a presenting
symptom of NCC [5]. McArthur made some relevant insights into
British soldiers with neurocysticercosis in the 1930s:
‘‘As well as gross disturbance which suggests diagnosis such as
these above, there may be mental dullness, impairment of
memory, temporary periods of disorientation, or a change in
disposition so that a previously efficient soldier may become
careless and untrustworthy. Indeed, Colonel Benson, commanding
the military hospital, Millbank, has told me with some feeling that
if any breach of ward discipline is reported, usually a cysticercosis
patient proves to be the delinquent [20].’’
Roselli et al. described a severe case of dementia associated with
parenchymal NCC in a 15-year-old girl [21]. Treatment with
praziquantal decreased intellectual deterioration but may have
precipitated hydrocephalus. Latovski et al. reported five patients
with NCC who presented to a New York hospital with signs of
dementia, seizures and increased intracranial pressure [22]. All
improved with surgical and/or medical therapy. Larger case series
have reported the prevalence of dementia between 6% [3] and
16% [4]. Psychotic behavior has been the presenting symptom in
individual NCC cases [5] and in 2% of 112 NCC cases from
Houston, TX [23].
Forlenza et al. reported on the psychiatric and cognitive
manifestations of NCC from a case series from Brazil [7]. All 38
NCC cases were examined cross-sectionally. The authors used the
mini-mental state exam, the present state exam, and Strub and
Black’s mental status examination to assess cognitive function.
Psychiatric disease was found in 66% of cases and cognitive
decline in 88%. Mild to moderate cognitive deficits were more
common than frank dementia. Interestingly, the number, type of
brain lesions, use of corticosteroids, or epilepsy did not significantly
correlate with the severity of psychiatric symptoms. The high rate
of cognitive impairment was striking considering the relative
insensitivity of the tests used.
The first study to use standardized cognitive testing in NCC
patients and controls was published in 1995 by Levav et al [8].
The authors recruited a representative community sample of
Table 4. SF-36 transformed scale scores for major quality-of-life outcomes at baseline and 6-month follow-up.
SF-36 Physical Function SF-36 Mental Health Function SF-36 Social Function
Group Baseline Follow-up Baseline Follow-up Baseline Follow-up
NCC 85.7 (4.4)* 91.3 (5.6) 57.4 (4.8)* 64.7 (5.1) 53.8 (5.6)**# 77.3 (5.3)#
Epilepsy Controls 85.0 (7.7) 90.0 (5.2) 50.3 (9.1)** 59.2 (5.4) 60.9 (10.3)* 68.2 (6.4)
Neighborhood Controls 98.2 (0.9) 97.8 (1.7) 73.8 (4.2) 76.4 (5.1) 84.4 (4.7) 83.4 (6.2)
*Difference vs. Neighborhood Controls cross-sectionally (p#0.07);
**Significant Difference vs. Neighborhood Controls cross-sectionally (p#0.05);
#Significant difference within groups longitudinally (p#0.05). Standard error follows transformed test scores in brackets.
doi:10.1371/journal.pntd.0001493.t004
Table 5. Individual cognitive test scores within the processing speed composite at baseline and 6-month follow-up.
Trail Making Test-Part B WAIS-III Digit Symbol-Coding Test
Group Baseline Follow-up Baseline Follow-up
NCC 31.3 (3.0)# 118.4 (19.8)# 50.6 (4.8)# 54.5 (5.2)#
Epilepsy Controls 40.0 (2.1) 73.0 (7.0) 66.9 (4.7) 71.7 (5.1)
Neighborhood Controls 36.4 (3.5) 93.6 (9.5) 59.0 (6.1) 62.7 (4.7)
#Significant difference within groups longitudinally (p#0.05). Standard error follows mean test scores in brackets.
doi:10.1371/journal.pntd.0001493.t005
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Ecuador. A total of 123 subjects agreed to participate in the study.
A series of 11 standardized NP tests were administered to 20
patients with NCC and controls to measure five dimensions of
neurocognitive function. The testing revealed that patients with
NCC had significant deficits in attention and motor control
compared with controls.
The most recent report on cognitive changes and NCC came
from Ciampi De Andrade et al [10]. This Brazilian group
recruited 40 treatment-naı ¨ve NCC cases, 49 healthy controls and
28 patients with cryptogenic epilepsy. The assessment of
neuropsychological function was cross-sectional with NCC cases
exhibiting significant impairment in executive function, memory,
constructive praxis and verbal fluency compared with healthy
controls and epilepsy controls. Similar to our study, there were no
significant predictors of cognitive dysfunction based on clinical
variables. In contrast to Ciampi De Andrade, et al, we did not find
the degree of cognitive dysfunction in our NCC cases. However,
the healthy controls in the study by Ciampi De Andrade, et al
were made up in part of staff at the hospital and the epilepsy
controls were established cases (vs. new cases) at the authors’
institution. The controls used could have produced some bias in
the cognitive testing results. For example, patients with established
epilepsy may have accommodated to any untoward effects of anti-
epileptic medications through modification of the dose or agent as
compared to new onset epilepsy cases. We recruited healthy
controls exclusively from the same neighborhood as cases and all
epilepsy controls had new onset seizures of unknown etiology.
These control groups mirrored the experience of NCC cases in our
population.
To our knowledge, there have been no longitudinal QoL studies
in patients with NCC. A recent cross-sectional study of QoL in
patients with NCC from Mexico reported deficits in both mental
and physical domains compared with controls [24]. Other
neurological conditions that have demonstrated impairments in
quality of life in Latin America include head trauma [25] and
spinal cord injury [26].
There are limitations to our study. Our sample size was
relatively small. This was due in part to the type of patients we
recruited, new onset patients with NCC with seizures, and the
longitudinal nature of the project. Second, we had relatively mild
disease burden of parenchymal NCC with low number of cysts
and few neurology symptoms outside of seizures. This is fairly
typical of patients with NCC in endemic regions and the US. A
more broad morbidity spectrum of NCC cases would likely
provide a wider range of cognitive dysfunction. Finally, it would
have been useful to have Peruvian neuropsychological test norms
for comparison in this study. Unfortunately, these data are lacking
for Peru and many Latin American countries. US norms were
available for the majority of the cognitive tests and served as a
reference for composite scores.
In summary, our study showed patients with parenchymal NCC
have mild cognitive dysfunction along with more significant
deficits in QoL compared with healthy neighborhood controls and
epilepsy controls. Altered mental status and psychiatric presenta-
tions in NCC are the tip of the iceberg while more subtle cognitive
dysfunction is quite common. Importantly, in our series, the
cognitive and QoL deficits improve with time. Future epidemio-
logic and clinical studies of NCC should include cognitive function
and QoL as outcome variables.
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